HC Wainwright Expects Higher Earnings for Alpha Tau Medical

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Investment analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Alpha Tau Medical in a report released on Tuesday, April 29th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.47) EPS.

Alpha Tau Medical Stock Down 0.8 %

Shares of Alpha Tau Medical stock opened at $2.60 on Thursday. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $4.39. The stock has a market cap of $182.99 million, a PE ratio of -6.05 and a beta of 0.93. The business has a fifty day simple moving average of $2.63 and a 200-day simple moving average of $2.85.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13).

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently bought and sold shares of DRTS. Levin Capital Strategies L.P. lifted its position in shares of Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after purchasing an additional 7,189 shares in the last quarter. Northern Trust Corp increased its stake in Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after buying an additional 25,770 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after buying an additional 26,800 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.